

CITATION REPORT

List of articles citing

Review article: anti-adhesion therapies for inflammatory bowel disease

DOI: 10.1111/apt.12639

Alimentary Pharmacology and Therapeutics, 2014, 39, 579-94

Source: <https://exaly.com/paper-pdf/58973506/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
144	Management of inflammatory bowel disease in poor responders to infliximab. 2014 , 7, 359-67		22
143	Coeliac Disease - New Pathophysiological Findings and Their Implications for Therapy. 2014 , 30, 156-65		6
142	Insights from immunology: new targets for new drugs?. 2014 , 28, 411-20		3
141	Etrolizumab in moderate-to-severe ulcerative colitis. 2014 , 384, 285-6		6
140	Not all monoclonals are created equal - lessons from failed drug trials in Crohn's disease. 2014 , 28, 437-49		36
139	Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases. 2014 , 43, 581-601		10
138	Vedolizumab: first global approval. 2014 , 74, 1293-303		14
137	Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. 2014 , 147, 981-9		75
136	The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. 2014 , 43, 525-41		34
135	Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. 2015 , 21, 21-46		108
134	Complications of biologics in inflammatory bowel disease. 2015 , 31, 296-302		15
133	Current understanding of alloimmunity of the intestinal graft. 2015 , 20, 286-94		11
132	Innovations in IBD treatment. 2015 , 13, 6-8		2
131	Angiogenesis in Inflammatory Bowel Disease. 2015 , 2015, 970890		51
130	Current stage in inflammatory bowel disease: What is next?. 2015 , 21, 11282-303		15
129	Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases. 2015 , 14, 1915-34		3
128	Integrins and adhesion molecules as targets to treat inflammatory bowel disease. 2015 , 25, 67-71		20

127	Targeting Integrins and Safety in an Emerging Class of Targeted Oral Therapies: Are We Prepared for Rational and Precision Choices?. 2015 , 149, 1669-72		3
126	Prediction of clinical pharmacokinetics of AMG 181, a human anti-IL17 monoclonal antibody for treating inflammatory bowel diseases. 2015 , 3, e00098		16
125	Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015 , 50, 43-52	2.4	22
124	Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. 2015 , 8, 66-82		92
123	Positioning Therapy for Ulcerative Colitis. 2015 , 17, 29		12
122	[Vedolizumab in the treatment of Crohn's disease]. 2015 , 38, 338-48		15
121	Vedolizumab for the treatment of moderately to severely active ulcerative colitis. 2015 , 35, 412-23		12
120	Introducing vedolizumab to clinical practice: who, when, and how?. <i>Journal of Crohn's and Colitis</i> , 2015 , 9, 356-66	1.5	44
119	Pyrrolidine Dithiocarbamate Inhibits NF-KappaB Activation and Upregulates the Expression of Gpx1, Gpx4, Occludin, and ZO-1 in DSS-Induced Colitis. 2015 , 177, 1716-28		27
118	ERRORES FRECUENTES EN EL DIAGNOSTICO Y TRATAMIENTO DE LOS PACIENTES CON ENFERMEDAD INFLAMATORIA INTESTINAL. 2015 , 26, 663-666		
117	Medical Therapy of Active Ulcerative Colitis. 2015 , 31, 236-45		4
116	Targeting of gut specific leucocyte recruitment in IBD by vedolizumab. 2015 , 64, 8-10		9
115	Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab. 2016 , 10, 33-52		8
114	Association Between Intercellular Adhesion Molecule-1, -2, -3 Plasma Levels and Disease Activity of Ankylosing Spondylitis in the Chinese Han Population. 2016 , 41, E618-24		3
113	Real World Experience With Natalizumab at a Tertiary Care Pediatric IBD Center. 2016 , 62, 863-6		8
112	Intestinal anti-inflammatory effects of total alkaloid extract from <i>Fumaria capreolata</i> in the DNBS model of mice colitis and intestinal epithelial CMT93 cells. 2016 , 23, 901-13		19
111	Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease. 2016 , 14, 1593-1601.e2		141
110	Effects of AVX-470, an Oral, Locally Acting Anti-Tumour Necrosis Factor Antibody, on Tissue Biomarkers in Patients with Active Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 641-9	1.5	19

109	Ameliorating Active Ulcerative Colitis via an Orally Available Toll-Like Receptor-9 Modifier: A Prospective Open-Label, Multicenter Phase II Trial. 2016 , 61, 3246-3254		9
108	Fabrication of a photo-crosslinked gelatin hydrogel for preventing abdominal adhesion. 2016 , 6, 92449-92453		15
107	The Complexity of alpha E beta 7 Blockade in Inflammatory Bowel Diseases. <i>Journal of Crohn's and Colitis</i> , 2017 , 11, 500-508	1.5	10
106	A review of the cost-effectiveness of vedolizumab for treating moderate- to severely active ulcerative colitis. 2016 , 16, 679-683		2
105	Targeting the complex interactions between microbiota, host epithelial and immune cells in inflammatory bowel disease. 2016 , 113, 574-584		18
104	Interactions Between Inflammatory Bowel Disease Drugs and Chemotherapy. 2016 , 14, 507-534		1
103	Luteolin ameliorates dextran sulfate sodium-induced colitis in mice possibly through activation of the Nrf2 signaling pathway. 2016 , 40, 24-31		54
102	8,9-Dehydrohispanolone-15,16-lactol diterpene prevents LPS-triggered inflammatory responses by inhibiting endothelial activation. 2016 , 473, 2061-71		6
101	Immune Based Therapies for Inflammatory Bowel Disease. 2016 , 37-61		
100	The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews. 2016 , 22, 1737-43		4
99	Predicting Therapeutic Response by in vivo Molecular Imaging in Inflammatory Bowel Diseases. 2016 , 34, 552-7		5
98	Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series. 2016 , 4, 97-104		38
97	Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies. 2016 , 18, 13		12
96	Vedolizumab in the treatment of Crohn's disease. 2016 , 10, 283-90		9
95	The Immunogenetics of Autoimmune Cholestasis. 2016 , 20, 15-31		17
94	The Gut-Liver Axis in Primary Sclerosing Cholangitis. 2016 , 20, 1-14		27
93	Monocyte adhesion to the endothelium is an initial stage of atherosclerosis development. 2016 , 58, e419-e425		48
92	Pathway-based approaches to the treatment of inflammatory bowel disease. 2016 , 167, 104-15		23

91	Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease. 2017 , 62, 1-16		60
90	Mucosal Antibodies to the C Terminus of Toxin A Prevent Colonization of Clostridium difficile. 2017 , 85,		17
89	Optimizing pharmacologic management of inflammatory bowel disease. 2017 , 10, 595-607		21
88	One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2017 , 46, 310-321	6.1	85
87	Melatonin alters amino acid metabolism and inflammatory responses in colitis mice. 2017 , 49, 2065-2071		10
86	Overcoming disease-specific matrix effect in a clinical pharmacokinetic assay using a microfluidic immunoassay technology. 2017 , 9, 1207-1216		6
85	Alicaforsen for the treatment of inflammatory bowel disease. 2017 , 26, 991-997		19
84	G protein-coupled receptor 35 contributes to mucosal repair in mice via migration of colonic epithelial cells. 2017 , 123, 27-39		25
83	Anti TNF- α therapy for ulcerative colitis: current status and prospects for the future. 2017 , 13, 223-233		47
82	Timing Strategies of Direct-Acting Antivirals and Biologics Administration in HCV-Infected Subjects with Inflammatory Bowel Diseases. <i>Frontiers in Pharmacology</i> , 2017 , 8, 867	5.6	7
81	Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles. <i>Frontiers in Immunology</i> , 2017 , 8, 764	8.4	33
80	Anti-Adhesion Therapies in Inflammatory Bowel Disease-Molecular and Clinical Aspects. <i>Frontiers in Immunology</i> , 2017 , 8, 891	8.4	40
79	Cutaneous Manifestations of Reactions to Biologics. 2018 , 18, 12		4
78	Addition of Granulocyte/Monocyte Apheresis to Oral Prednisone for Steroid-dependent Ulcerative Colitis: A Randomized Multicentre Clinical Trial. <i>Journal of Crohn's and Colitis</i> , 2018 , 12, 687-694	1.5	7
77	Review article: novel oral-targeted therapies in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1610-1622	6.1	28
76	Immunotherapy in inflammatory bowel disease: Novel and emerging treatments. 2018 , 14, 2597-2611		22
75	Review article: nonclinical and clinical pharmacology, pharmacokinetics and pharmacodynamics of etrolizumab, an anti- $\alpha 4\beta 7$ integrin therapy for inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 1440-1452	6.1	19
74	Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018 , 47, 753-762	6.1	45

73	IL-8 antagonist, CXCL8(3-72)K11R/G31P coupled with probiotic exhibit variably enhanced therapeutic potential in ameliorating ulcerative colitis. <i>Biomedicine and Pharmacotherapy</i> , 2018 , 103, 253-261	7.5	17
72	New treatment options for inflammatory bowel diseases. 2018 , 53, 585-590		98
71	Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. 2018 , 24, 849-860		24
70	Protein Turnover Measurements in Human Serum by Serial Immunoaffinity LC-MS/MS. 2018 , 64, 279-288		13
69	A comprehensive review and update on Crohn's disease. 2018 , 64, 20-57		163
68	The impact of biological interventions on health-related quality of life in adults with Crohn's disease. <i>The Cochrane Library</i> , 2018 ,	5.2	0
67	Novel treatments for inflammatory bowel disease. 2018 , 33, 20-27		20
66	Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s. 2018 , 24, 1237-1250		17
65	Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1. <i>Journal of Crohns and Colitis</i> , 2018 , 12, S669-S677	1.5	21
64	Therapeutic potential of dinitrobenzene sulfonic acid (DNBS)-induced colitis in mice by targeting IL-1 β and IL-18. 2018 , 155, 150-161		25
63	PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. 2018 , 27, 623-629		3
62	IL-8 analogue CXCL8 (3-72) K11R/G31P, modulates LPS-induced inflammation via AKT1-NF- κ B and ERK1/2-AP-1 pathways in THP-1 monocytes. 2018 , 79, 809-816		9
61	Systematic Review with Network Meta-Analysis: Efficacy of Induction Therapy with a Second Biological Agent in Anti-TNF-Experienced Crohn's Disease Patients. 2018 , 2018, 6317057		11
60	Activation of Resolution Pathways to Prevent and Fight Chronic Inflammation: Lessons From Asthma and Inflammatory Bowel Disease. <i>Frontiers in Immunology</i> , 2019 , 10, 1699	8.4	29
59	Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease. <i>Frontiers in Pharmacology</i> , 2019 , 10, 39	5.6	15
58	Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multi-centre cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019 , 50, 40-53	6.1	29
57	Precision medicine in primary sclerosing cholangitis. 2019 , 20, 346-356		4
56	Oligonucleotides-A Novel Promising Therapeutic Option for IBD. <i>Frontiers in Pharmacology</i> , 2019 , 10, 314	5.6	13

55	Novel Non-biologic Targets for Inflammatory Bowel Disease. 2019 , 21, 22		8
54	ILC3 function as a double-edged sword in inflammatory bowel diseases. 2019 , 10, 315		79
53	Therapy for Crohn's Disease. 2019 , 150-172		
52	Ulcerative Colitis. 2019 , 173-186		1
51	Anti-trafficking agents in the treatment of inflammatory bowel disease. 2019 , 35, 499-506		2
50	Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. 2019 , 25, 270-282		32
49	Towards improved control of inflammatory bowel disease. 2019 , 89, e12745		14
48	A State-of-the-Art Review of New and Emerging Therapies for the Treatment of IBD. 2019 , 25, 820-830		50
47	Biological therapies in inflammatory bowel disease: Beyond anti-TNF therapies. 2019 , 206, 9-14		39
46	Ulcerative Colitis Patients Continue to Improve Over the First Six Months of Vedolizumab Treatment: 12-Month Clinical and Mucosal Healing Effectiveness. 2020 , 3, 74-82		1
45	Vedolizumab Therapy in Children With Primary Sclerosing Cholangitis: Data From the Pediatric Primary Sclerosing Cholangitis Consortium. 2020 , 71, 459-464		2
44	Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK - a retrospective observational study. <i>Scandinavian Journal of Gastroenterology</i> , 2020 , 55, 907-916	2.4	2
43	Integrin-mediated adhesive properties of neutrophils are reduced by hyperbaric oxygen therapy in patients with chronic non-healing wound. <i>PLoS ONE</i> , 2020 , 15, e0237746	3.7	8
42	Synthesis of novel 2, 3, 5-tri-substituted thiazoles with anti-inflammatory and antibacterial effect causing clinical pathogens. <i>Journal of Infection and Public Health</i> , 2020 , 13, 472-479	7.4	9
41	Close homolog of L1-deficient ameliorates inflammatory bowel disease by regulating the balance of Th17/Treg. <i>Gene</i> , 2020 , 757, 144931	3.8	2
40	Maintenance of Remission Among Patients With Inflammatory Bowel Disease After Vedolizumab Discontinuation: A Multicentre Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2020 , 14, 896-903	1.5	4
39	Targeting the cutaneous lymphocyte antigen (CLA) in inflammatory and neoplastic skin conditions. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 275-282	5.4	3
38	Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins?. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 353-361	5.4	3

37	The Antioxidant and Anti-Inflammatory Properties of L. Cashew Nuts in a Mouse Model of Colitis. <i>Nutrients</i> , 2020 , 12,	6.7	44
36	Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1893-1904	4	3
35	Morbus Crohn. 2021 , 234-247		
34	Leukocyte Integrin Antagonists as a Novel Option to Treat Dry Age-Related Macular Degeneration. <i>Frontiers in Pharmacology</i> , 2020 , 11, 617836	5.6	4
33	Ulcerative Colitis in Children and Adolescents. 2021 , 474-492.e8		0
32	New Therapeutics for Ulcerative Colitis. <i>Annual Review of Medicine</i> , 2021 , 72, 199-213	17.4	7
31	Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. 2021 , 9,		11
30	Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study. <i>European Journal of Pediatrics</i> , 2021 , 180, 3029-3038	4.1	1
29	Implications of lymphatic alterations in the pathogenesis and treatment of inflammatory bowel disease. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 140, 111752	7.5	5
28	Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy. <i>Frontiers in Immunology</i> , 2021 , 12, 711217	8.4	1
27	Small molecule drugs in the treatment of inflammatory bowel diseases: which one, when and why? - a systematic review. <i>European Journal of Gastroenterology and Hepatology</i> , 2020 , 32, 669-677	2.2	7
26	CRK proteins selectively regulate T cell migration into inflamed tissues. <i>Journal of Clinical Investigation</i> , 2015 , 125, 1019-32	15.9	33
25	Methionine restriction on oxidative stress and immune response in dss-induced colitis mice. <i>Oncotarget</i> , 2017 , 8, 44511-44520	3.3	40
24	A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. <i>ClinicoEconomics and Outcomes Research</i> , 2014 , 6, 431-43	1.7	11
23	Sesquiterpenes from Myrrh and Their ICAM-1 Inhibitory Activity In Vitro. <i>Molecules</i> , 2020 , 26,	4.8	1
22	Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease. <i>Gut and Liver</i> , 2019 , 13, 604-616	4.8	35
21	Novel Biologics for the Treatment of Ulcerative Colitis. 2014 , 191-207		
20	Morbus Crohn. 2015 , 1-12		

19	Anti-MAdCAM antibody for induction of remission in ulcerative colitis. <i>The Cochrane Library</i> ,	5.2	
18	The Immunology of the Gastrointestinal System. 2016 , 1-22		
17	Factors Contributing to the Preference of Korean Patients with Crohn's Disease When Selecting an Anti-Tumor Necrosis Factor Agent (CHOICE Study). <i>Gut and Liver</i> , 2016 , 10, 391-8	4.8	8
16	Intestinal Failure-Associated Liver Disease. 2016 , 335-347		
15	Morbus Crohn. 2018 , 361-372		
14	Morbus Crohn. 2019 , 196-208		
13	A SPECIAL MEETING REVIEW EDITION: CCFA/Advances in Inflammatory Bowel Diseases 2015: Highlights in Ulcerative Colitis and Crohn's Disease: A Review of Selected Presentations From the CCFA/Advances in Inflammatory Bowel Diseases 2015 Clinical and Research Conference □ December 10-12, 2015 [Orlando, Florida]Special Reporting on:□New and Future Adhesion	0.7	2
12	Vedolizumab as a Treatment for Crohn's Disease and Ulcerative Colitis. <i>Gastroenterology and Hepatology</i> , 2014 , 10, 793-800 multicenter, Double-Blind, Placebo-. <i>Gastroenterology and Hepatology</i> , 2016 , 12, 1-20	0.7	4
11	[Research frontier of inflammatory bowel disease]. <i>Zhejiang Da Xue Xue Bao Yi Xue Ban = Journal of Zhejiang University Medical Sciences</i> , 2019 , 48, 334-341		1
10	Effects of UV/HO degradation and step gradient ethanol precipitation on Sargassum fusiforme polysaccharides: Physicochemical characterization and protective effects against intestinal epithelial injury.. <i>Food Research International</i> , 2022 , 155, 111093	7	0
9	Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis.. <i>Digestive and Liver Disease</i> , 2021 ,	3.3	1
8	The impact of vedolizumab and ustekinumab on articular extra-intestinal manifestations in inflammatory bowel disease patients: a real-life multicentric cohort study.. <i>Journal of Crohn's and Colitis</i> , 2022 ,	1.5	1
7	Image_1.TIF. 2019 ,		
6	Image_2.TIF. 2019 ,		
5	Data_Sheet_1.DOCX. 2019 ,		
4	Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs.		
3	Applications and Pharmacological Properties of Cactus Pear (Opuntia spp.) Peel: A Review. 2022 , 12, 1903		1
2	Role of CD34 in inflammatory bowel disease. 14,		0

- 1 Real-world efficacy and safety of vedolizumab in managing ulcerative colitis versus Crohn's disease: results from an Italian multicenter study. **2023**, 23, 293-304

○